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A prospective study was carried out, to identify the drug related problems and to prevent or to solve the 
negative outcomes associated with medication of the geriatric patients that consumed psychoactive drugs, 
who were hospitalized. The study was carried out according to the DADER Method of Pharmacotherapy 
Monitoring, adapted to the Hospital’s environment and the theoretical rationale of the Third Consent 
of Granada was assumed, for the considerations related to the drug related problems and the negative 
outcomes associated with medication. Thirty five patients were included whose ages ranged between the 
60 and 90 years. Thirty six negative associated outcomes were identified, in 34 patients that represented 
97.14% incidence. A prevalence of the negative outcomes associated with the necessity was observed, 
followed by those associated with the security. The inadequate drug uses was the drug related problem 
that prevailed in the sample. The psychoactive drugs that were related with these results were mainly 
the anxiolytics, meprobamate and the neuroleptics. Some 82.35% of the interventions were accepted, 
achieving resolution of 47.06% of the negative outcomes associated with medication.
Uniterms: Medication/associated negative outcomes. Psychoactive drugs/geriatric use. Geriatric patients/
use of psychoactive drugs.
Foi realizada uma pesquisa de intervenção, prospectiva, a fim de identificar problemas relacionados aos 
medicamentos e evitar ou resolver resultados negativos daí decorrentes, em pacientes idosos que faziam 
uso de medicamentos psicotrópicos e que foram internados. O estudo foi realizado de acordo com o 
método DADER para o acompanhamento farmacoterapêutico e assumiram-se os pressupostos teóricos do 
III Consenso de Granada, as considerações relacionadas com os problemas dos fármacos e os resultados 
negativos associados à medicação. Foram incluídos 35 pacientes com idades entre 60 e 90 anos. Trinta 
e seis RM foram identificados em 34 pacientes representando incidência de 97,14% e a prevalência foi 
observada para os resultados negativos associados com a necessidade, seguidos por aqueles relacionados 
à segurança. O uso indevido de fármacos foi os problema mais frequente na amostra. Os psicofármacos 
mais implicados foram os ansiolíticos, meprobamato e neurolépticos. Das intervenções, 82,35% foram 
aceitas, alcançando 47,06% de resolução dos resultados negativos associados à medicação. 
Unitermos: Medicação/resultados negativos associados. Medicamentos psicotrópicos/uso em geriatria. 
Pacientes geriátricos/uso de psicotrópicos.
INTRODUCTION
The increase in life expectancy has determined pro-
gressive population aging, and Cuba is not exempt from 
this situation. Statistics show that older people represents 
more than the 15% of the population (Menchaca, 2011). 
Between 81 and 85% of them consumes some drug (Peña, 
et al., 2003; Santana et al., 2007). Psychotropic drugs one 
of the groups of drugs that are prescribed more frequently 
in this population, represented in a higher frequency by 
benzodiazepines, antidepressants, and neuroleptics, which 
are used fundamentally against insomnia and anxiety 
(Aparasu, Mort, 2004; Aparasu, Mort, 2000).
Nowadays, one of the goals of medicine is to provide 
good health attention to all people older than 65 that inhabit 
and will inhabit our planet, they represent a large population 
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sector. . The challenge for the 21st Century is the improve-
ment of life quality to “give our age more life and more 
years to our lives” (Werbin, 2006). An appropriate strategy 
to achieve this is the individualized pharmacotherapy moni-
toring through the development of Pharmaceutical Care, 
since Drug Related Problems (DRP) are common in the 
geriatric population, which are caused by polypharmacy, 
physiological changes related to age, the pharmacokinet-
ics, and the pharmacodynamics. That is why, very general 
guidelines should be avoided, and individualized strategies 
should be used, which should be the best for every patient 
and every situation, where pharmacist-physician-patient 
communication and individualized pharmacotherapy moni-
toring are the most important.
METHODS
A prospective and intervention research was carried 
out with the purpose of identifying the DRP and preventing 
or solving the negative outcomes associated to them. This 
research was carried out with aged patients that consumed 
psychotropic drugs and that were hospitalized in the Intern 
medicine service of the Saturnino Lora Hospital, in San-
tiago de Cuba; in the period of four months.
The DADER method was used for the Pharmaco-
therapy Monitoring (Sabater et al., 2007), adapted to the 
Hospital’s environment (Faus et al., 2008), and the theo-
retical methods that were used were the ones proposed by 
the Third Grenada Consensus, 2007 (Comité de Consenso, 
2007). We carried out the steps listed below:
● The participation of pharmacists in the clinical ses-
sions of internal medicine
● The participation of pharmacists in the pass with 
their health care plan
● Daily updated medication to the patient
● Interviewing the patient and their caregivers
● Resolve queries generated daily about drug therapy 
in the hospital service.
● Inform the patient about their medication during 
hospitalization and especially on hospital discharge, 
including information about the need to continue 
with the monitoring program for community phar-
macists.
●  Inform the health care team about the drug conti-
nuously, even after hospital discharge the patient.
Pharmacotherapy follow-up to develop the 
following stages were followed
Service offer
The offer of the service is performed from the Phar-
macy Department; the Department of Internal Medicine, 
pointing out the interest of geriatric consumers including 
psychiatric drugs. For patient choice and service objec-
tives of Pharmacotherapy follow-up, we took into account 
the medical criteria established by the heads of Internal 
Medicine.
After the doctor decided to include prospective 
patients in the study, informed consent was sought from 
the patient or caregiver, after explaining the guarantee of 
confidentiality of personal information, the purpose and 
usefulness of research to get the most benefit of phar-
macotherapy with the least possible risk. Consent for 
participation was obtained by writing in the presence of 
the caregiver.
Pharmaceutical Interview 
The first interview was conducted after observ-
ing the physician’s assessment of income. Before the 
interview, the pharmacist should know the patients 
condition and have information about their medical 
history to detect indications of psychotropic drugs, and 
avoid unnecessary questions. In this interview emphasis 
took place on medication before hospitalization (which 
medicines were brought from home to hospital and which 
continued to take, or which suspended). This allowed 
the detection of drugs administered by self-medication 
and drug imposed for health problems suffered by the 
patient hospitalization. During the interview the pres-
ence of the caregiver was allowed, not only because in 
the hospital the patient can see his altered state of con-
sciousness, but because it provides relevant information 
and actively involves in patient care while hospitalized, 
in addition to the characteristics the elderly patient. This 
moment became an opportunity to educate the patient 
and caregiver.
The information obtained was supplemented by 
medical records and nursing records. This information 
was updated through pharmacist participation in clinical 
sessions and the hall pass. Medical records and nursing 
records were consulted regularly. This allowed the devel-
opment, in the most updated possible pharmacotherapeutic 
history of the patient during their hospital stay.
Status report
How the hospitalized patient was evolving and the 
many states of affairs during their hospital stay as well 
because of a limitation in the hospital, the patient can 
not give all the necessary information about their health 
problems and medication, to improve the record, this was 
supplemented with data from the daily review of medical 
records, nursing logs.
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Phase of study
The study focused primarily on the diagnosis of the 
incoming patient, which determines the main performance 
of the health team to treat the patient. From the estab-
lished medical intervention, the pharmacist determined 
how the drug could contribute to the objectives pursued 
by the health team during the hospital stay. In the event 
that the use of psychotropic medication was detected by 
self-medication or a medical indication was reported prior 
to the doctor taking this into account in the procedures to 
follow in the pharmacotherapy. In this phase we studied 
the health concerns of the patient (or caregiver), related to 
the reason for admission, principal diagnosis, secondary 
diagnoses.
Evaluation Phase
We performed as quickly as possible, not only for the 
rapid evolution of the patient (which can vary in hours or 
minutes depending on the particular clinical situation of 
the case), but it should also meet the expectations of the 
health team, so justifying the presence of a pharmacist in 
the hospital service.
After identification of potential negative outcomes 
associated with medication (NOM) in the patient, they were 
studied with other pharmacists, before their approach to 
service practitioners.
Intervention phase
We designed an action plan that took into account the 
best possible strategy to solve the NOM, and therapeutic 
goals to achieve in the short, medium and long term, ac-
cording to the health care team, patient and their caregivers.
Interview with the patient and results of pharmaceu-
tical interventions: In the hospital, the constant presence 
of doctors and nurses allowed rapid communication that 
facilitated the resolution of NOM, but presented the NOM 
limiting those associated with the use of drugs indicated 
by other non-specialists of the hospital.
In addition to educational interventions during the 
hospital stay, each patient or caregiver was given the report 
on hospital discharge following the steps proposed for 
written communication between professionals, to resolve 
potential NOM in the community pharmacy. This format 
included the following points: 1) patient presentation; 2) 
medications administered during hospitalization; 3) pa-
rameters, signs or symptoms related to the medication to 
determine the patient’s progress and to be assessed after 
discharge; 4) trial pharmacist (also included here is the 
need to educate to avoid self-medication and a problem 
with the patients previous medication must be taken into 
account, and 5) dismissal by the doctor responsible for the 
patient and the pharmacist who made SFT.
Medical intervention were used to evaluate the pa-
tient’s pharmaceutical monitoring results, NOM was used 
as an indicating element for the solution or prevention. 
The classification listed below was used:
● Solved NOM: It’s when the NOM is solved whether 
the pharmaceutical intervention is accepted or not.
● Not solved NOM: It’s when the NOM is not solved 
whether the pharmaceutical intervention is accepted 
or not.
● Prevented NOM: When a high probability of nega-
tive results due to medication were expected, by the 
patient’s manipulation to mask the negative results. 
RESULTS
In this research 35 patients, between 60 and 90 years 
old were included, where 36 NOM were identified in 34 
patients, which represented a 97.14% incidence. So, every 
patient was probably exposed to 1.06 NOM. A prevalence 
of the negative results associated to need was observed 
with 50%, followed by the ones associated with safety 
with 38.89%, being the effectivity associated problems 
represented by 11.11%.
In the Table I, are reflected the NOM and the DRP 
that caused the problems mentioned previously, specifying 
the drugs most implicated in each case. 
The effect of the inappropriate drug was seen in 50% 
of the patients, and 27.78% of them was related to anxio-
lytic use, and 13.89% was related to meprobamate. To a 
minor extent, amitriptyline, thioridazine and phenobarbital 
were used with no need in some patients, the inappropri-
ate prescription being detected as a cause in the last two.
In the cases where non quantitative ineffectiveness 
was detected (11. 11%), the cause was the drug interac-
tion (phenobarbital /nifedipine; diazepam/phenytoin), 
which led in both cases to subtherapeutical levels of the 
drugs (phenobarbital and phenytoin) with the consequent 
therapeutical failure.
Any negative outcomes were not detected associated 
to the quantitative ineffectiveness and safety.
The non-quantitative safety problem was detected in 
38.89% of the patients, being the neuroleptics and antiepi-
leptics; with 13.89 and 8.33% respectively, the principal 
representatives, which had the adverse drug effects as a 
cause. The interaction between drugs was the fundamental 
cause of the appearance of non quantitative safety, repre-
senting 57.14% of the total cases detected, with the inter-
action of phenytoin with nifedipine the highest incidence. 
The likelihood of extrapyramidal effects, was probably 
related to the use of haloperidol in 13.89% of patients 
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being diagnosed in 2.78% of the Parkinson Syndrome’s 
sample. One Stevens - Johnson syndrome was diagnosed 
which might be responsible for non quantitative safety in 
the use meprobamate.
Every patient was exposed approximately to a 1.76 
DRP, since the detected or prevented NOM were associ-
ated with 44 DRP, which are reflected in the Table II. It is 
important to observe that the problems that were involved 
to a higher extent with negative results, was the inadequate 
drug use with a 36.4% . The detection of the adverse drug 
reaction and the drug interaction, which provoked their 
manifestation or therapeutic ineffectivity, were the other 
TABLE I - Incidence of DRP according to the type of NOM
Type of NOM Implicated drugs NOM´s Incidence DRP/references
# %
A Not found 0 0 Not found
B Chlordiazepoxide, Nitrazepam, 
Diazepam
10 27.78 Inadequate drug use (Beers, 1991; 
Beers, 1997; Fick, et al, 2003)
Meprobamate 5 13.89 Inadequate drug use/(Beers, 1991; 
Beers, 1997; Fick, et al, 2003 )
Amitriptyline 1 2.78 Inadequate drug use/(Beers, 1991; 
Beers, 1997; Fick, et al, 2003)
Thioridazine 1 2.78 Inadequate prescription (Fick, et al, 2003)
Phenobarbital 1 2.78 Inadequate prescription/
(Armijo, 1998; Zarranz,, 1996)
C Phenobarbital /Nifedipine 2 5.56 Drug Interaction 
Diazepam/Phenytoin 2 5.56 Drug Interaction/ (MINSAP, 2006) 
D Not found 0 0 Not found
E Not found 0 0 Not found
F Haloperidol 5 13.89 Probability of adverse effect
Meprobamate 1 2.78 Probability of adverse effect
Phenytoin/Nifedipine 3 8.33 Drug Interaction/(Garcia, et. al., 1998; 
MINSAP, 2006) and probability 
of adverse effect
Meprobamate/ Nitrazepam 1 2.78 Drug Interaction/(MINSAP, 2006) and 
probability of adverse effect
 Haloperidol/Phenobarbital 1 2.78 Drug Interaction/(MINSAP, 2006) and 
probability of adverse effect
Trihexyphenidyl/Haloperidol 1 2.78 Drug Interaction/(MINSAP, 2006) and 
probability of adverse effect
Chlordiazepoxide/ Cimetidine 1 2.78 Drug Interaction/(MINSAP, 2006) and 
probability of adverse effect
Phenytoin/ Tolbutamide 1 2.78 Drug Interaction/(MINSAP, 2006) and 
probability of adverse effect 
Total 36 100
A= Untreated health problem; B= Effect of unnecessary medicine; C =Non quantitative ineffectiveness; D = Quantitative 
Ineffectiveness; E = Quantitative safety; F = Non quantitative safety.




Drug Interaction 12 27.3 
Inadequate drug use 16 36.4 
Inadequate prescription 2 4.5 
Probability of adverse effects 14 31.8
TOTAL 44 100
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Solved Non solved Prevented
# % # % # % # %
Accepted intervention 8 47.06 - - 6 35.29 14 100 
Non accepted intervention - - 3 17.65 3 100
Total 8 47.06 3 17.65 6 35.29 17 100
causes that could have provoked a NOM with a higher fre-
quency; represented respectively with a 31.8% and 27.3%.
The psychotropic agents that provoked the NOM 
were, in first place, the anxiolytics (diazepam, nitrazepam, 
chlordiazepoxide) with a 36.11%, followed by neurolep-
tics (haloperidol, thioridazine) with 22.22% and the use 
of meprobamate being found with a 19.44% incidence. 
Interventions to resolve the effect of unnecessary 
drugs associated with inadequate drug use was made 
directly to the patient or caregiver through educational 
interventions. Similarly in the case of the NOM associated 
with the non-quantitative pharmacotherapeutic safety were 
monitored and only the physician intervention was per-
formed in cases which manifested the NOM. Interventions 
being made by medical personnel only when the criterion 
was essential to resolve the NOM itself or in cases where 
the possibility of high expression was presented and high 
risk to the patient.
Seventeen interventions by Physician were carried 
out, where the 82.35% of them was accepted, which al-
lowed 47.06% of the NOM to be solved (Table III).
The none acceptation of the interventions happened 
in 17.65% of the cases, having as a basis the existence of 
other elements in the patient that could have led to the de-
tected health problem or of a previously imposed therapy, 
which should have been evaluated by the specialist.
Many educative interventions were done the day 
before the patients were going home to 100% of the ones 
researched. The therapy that every patient should continue 
and the possible non-compliance risks was analyzed. How 
to conserve the drugs and what to do in case of forgetting 
one dose was explained. The risks of self-medication were 
emphasized.
DISCUSSION
In relation to the NOM incidence in the sample, the 
results have to do with the ones of other researches (Blakey, 
Hixson-Wallace, 2000), where approximately 1.24 NOM 
per patient has been found, with a huge incidence of the ef-
fect of unnecessary medicine use on aged people.
Our study revealed that 45.71% of the patients were 
treated with psychoactive drugs potentially inappropriate 
use in geriatrics, independent of disease or condition. The 
most commonly inappropriately prescribed medication 
was chlordiazepoxide, diazepam (27.78%) and mepro-
bamate (13.89%). Other study reveal values  similar to 
those identified in relation to the use of potentially inap-
propriate medication (Beers, 1991; Beers, 1997; Stuch et 
al., 1994; Pardo et al., 2003; Bandrés et al., 2008), which 
exposes the elderly to unnecessary risks such as adverse 
effects of a worsening of the quality of life, increased 
hospitalizations and increased health spending (Jano et 
al., 2007).
The use of phenobarbital in epileptic patients who 
were seizure free for over five years was considered un-
necessary, so it could be suppressed with the drug therapy 
based on publications that they refer (Armijo, 1998; Zar-
ranz, 1996). In the other patient the effect of unnecessary 
medicine (thioridazine) was detected, they suffered severe 
hypertensive cardiac disease, which is contraindicated 
(MINSAP, 2006).
The interaction between diazepam and phenytoin 
possibly was responsible for non quantitative ineffective-
ness detected in 5.56% of the patients. By removing the 
benzodiazepine adequate seizure control was achieved. 
Several studies show that serum levels of phenytoin may 
decrease or increase when this drug is used concomitantly 
with diazepam. Diazepam is one example of a drug that is 
extensively metabolized by CYP2C19 and could poten-
tially influence phenytoin elimination by acting as an alter-
nate substrate for this isoenzyme (Murphy, Wilbur, 2003).
The combination of phenobarbital/nifedipine may 
lead to non quantitative ineffectiveness; this is explained 
taking into account that phenobarbital causes an increase 
in the activity of the enzyme induction of synthesis of 
cytochrome P-450, cytochrome P-450 reductase and 
other enzymes involved in the metabolism of nifedipine. 
In addition to phenobarbital increases hepatic blood flow 
(MINSAP, 2006).
The quantitative insecurity because of the likeli-
hood of increased adverse effects of phenytoin inter-
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action with nifedipine occurred in 8.33% of patients 
which can be explained by increased circulating levels 
of phenytoin can presented in patients treated with nife-
dipine, by reducing the hepatic first, and compete with 
this by binding to plasma proteins (Garcia et. al., 1998; 
MINSAP, 2006).
The prevalence of psychotropic drug use for the 
treatment of insomnia could have been caused by the fact 
that this is very frequent in aged people, because of the 
minor need of sleep at this age, and because of the pres-
ence of chronic illness (with symptoms of pain, dyspnea, 
polyachiuria), the use of drugs that can alter not only 
the quantity, but also the quality of sleep; and also psy-
chiatric illnesses like depression, anxiety, and dementia 
(Gil, 1996). It is said, that the most used drugs in aged 
people are psychotropics ((Mattiussi, 2004; Aparasu, 
Mort, 2004; Aparasu, Mort, 2000). It is important to say 
that 33.33% of the patients were treated with drugs that 
could cause insomnia, and the 46.67% were treated with 
diuretics, that sometimes, were supplied in the afternoon 
or in the evening, causing sleep´s alterations due to night 
polyuria.
The use of inadequate drugs, of which the DRP 
with a high frequency, was related to the use of chlor-
diazepoxide, diazepam, nitrazepam, amitriptyline and 
meprobamate. According to reports (Merck, 1999; Fick 
et al., 2003), the anxiolytic of half long duration are not 
the most adequate drugs for aged people, because they 
cause long term sedation, increasing the risk of falls 
and fractures. In the same way, amitriptyline and chlor-
diazepoxide, due to their anticholinergic and sedating 
properties, are not the best choice for elderly patients. 
Meprobamate produces sedation relatively easily, that is 
why all the drugs were inadequately used in the patients 
of the sample (Beers, 1997; Fick et al., 2003; Pardo et 
al., 2003; Bandrés et al., 2008).
Old people have a bigger risk of toxicity, and of 
developing dependence on some drugs, especially with 
the long duration like benzodiazepines. That is why they 
should be avoided. So, the half duration benzodiazepines 
will be carefully used, choosing the minimal doses and the 
drug of minor activity (Gil, 1996; Merck, 1999).
The prescription of barbiturates in old people 
should be reserved for convulsion treatment, because they 
provoke more adverse effects than the majority of other 
hypnotic and sedatives in these people, and also produce 
dependence more easily; besides, they may precipitate 
depression states (Merck, 1999) that occasionally justify 
the increase of the number of drugs in the patient’s phar-
macotherapy. The barbiturates use in aged patients has 
many disadvantages, such as: tendency to developing hab-
its, severe drug interactions, enzymatic hepatic problems 
and rebound phenomena like agitation and delirium. For 
all these reasons, this is contraindicated in the insomnia 
treatment (Gil, 1996).
It is known that the probability of the detection 
of the adverse drug reaction increases when people 
get older, some authors refer that adverse reactions are 
duplicated in these patients (Werbin, 2006). Among the 
adverse effects of the medication to aged people, is Par-
kinson’s induced by drugs (Preston et al., 2006), which 
was detected in a patient and attributed to the haloperidol 
use. This is the reason why the basis pathologies must be 
taken into account.
The factors of the adverse drug reaction risk in aged 
patients depend on many reasons, among them, advanced 
age, high number of drugs, higher doses and long treat-
ments, previous adverse reactions, underlying illnesses, 
inadequate clinical valuation, wrong therapeutical ac-
complishment, self-medication and altered nutritional 
condition (Werbin, 2006; De la Serna, 2000). The majority 
of these factors were found in the sample.
The psychopharmacologic treatment should be 
based on a careful diagnostic, and it should be used as 
long as the relationship benefit- risk is clearly favorable, 
trying to suspend the drugs as soon as the patient gets bet-
ter, except for the cases where relapses must be prevented 
(Werbin, 2006).
In the United Kingdom (Vicent et al., 2001), 11% 
of the hospitalized patients suffers an adverse effect; and 
the half of them could have been prevented. We agree with 
this approach because with the obtained results it can be 
said that with an integral work of the health team, it is pos-
sible to avoid most of the DRP that lead to NOM, where 
educative interventions to the patients and the health team 
are very important. 
There are few prospective researches about pharma-
cological interactions in elderly people. A research shows 
that 40% of the ambulatory patients are at risk of suffering 
the consequences of pharmacological interactions, and 
27% of them are potentially severe (Merck, 1999). These 
reports exceed the ones detected in this research, where a 
34.28% were exposed to a drug interaction; the 33.33% 
of them were responsible for a therapeutical ineffectivity, 
and 66.7% increasing the probability of the adverse drug 
reaction.
The achieved results with the proposed interventions 
by the Physician corresponded to the ones achieved in 
similar researches, where the acceptation of the interven-
tions was represented the following way: 74. 7 (Bonilla et 
al., 2009), 88. 8 (Galindo et al., 2003), and 91% (Garzas 
et al., 2003).
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CONCLUSIONS
A prevalence of the negative outcomes associated 
with the necessity was observed, followed by those as-
sociated with the security. The inadequate drug use and 
the probability of adverse effects were the drug related 
problems that prevailed in the sample. The psychoactive 
drugs that were related with these results in the main were 
anxiolytics, neuroleptics and meprobamate. 
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